Compare Stocks: CMMB, OKYO, PLRX, and YARW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$2.38 -4.0%	$2.10	$1.35 ▼ $3.58	$17.97M	0.76	121,947 shs	132,995 shs
OKYO OKYO Pharma	$1.35 +1.5%	$1.51	$1.28 ▼ $3.20	$69.80M	0.03	77,215 shs	98,709 shs
PLRX Pliant Therapeutics	$1.14 +2.7%	$1.11	$1.02 ▼ $1.95	$68.73M	1.27	363,285 shs	324,683 shs
YARW Yarrow Bioscience	$28.68 +1.3%	$0.00	$15.00 ▼ $46.95	$75.55M	2.01	128,270 shs	104,764 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-4.98%	+1.22%	+14.81%	+65.33%	-6.42%
OKYO OKYO Pharma	-2.21%	-5.00%	-13.64%	-15.82%	-32.83%
PLRX Pliant Therapeutics	0.00%	-3.48%	-3.90%	-4.31%	-22.38%
YARW Yarrow Bioscience	-3.38%	+7.77%	-22.30%	+2,829,999,900.00%	+2,829,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$2.38 -4.0%	$2.10	$1.35 ▼ $3.58	$17.97M	0.76	121,947 shs	132,995 shs
OKYO OKYO Pharma	$1.35 +1.5%	$1.51	$1.28 ▼ $3.20	$69.80M	0.03	77,215 shs	98,709 shs
PLRX Pliant Therapeutics	$1.14 +2.7%	$1.11	$1.02 ▼ $1.95	$68.73M	1.27	363,285 shs	324,683 shs
YARW Yarrow Bioscience	$28.68 +1.3%	$0.00	$15.00 ▼ $46.95	$75.55M	2.01	128,270 shs	104,764 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-4.98%	+1.22%	+14.81%	+65.33%	-6.42%
OKYO OKYO Pharma	-2.21%	-5.00%	-13.64%	-15.82%	-32.83%
PLRX Pliant Therapeutics	0.00%	-3.48%	-3.90%	-4.31%	-22.38%
YARW Yarrow Bioscience	-3.38%	+7.77%	-22.30%	+2,829,999,900.00%	+2,829,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
OKYO OKYO Pharma	2.50	Moderate Buy	$5.67	319.75% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	163.16% Upside
YARW Yarrow Bioscience	2.33	Hold	$58.00	102.23% Upside

Current Analyst Ratings Breakdown

Latest CMMB, OKYO, PLRX, and YARW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/3/2026	YARW Yarrow Bioscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$58.00
7/28/2026	YARW Yarrow Bioscience	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/17/2026	OKYO OKYO Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A
PLRX Pliant Therapeutics	$1.58M	44.68	N/A	N/A	$2.95 per share	0.39
YARW Yarrow Bioscience	$570K	134.34	N/A	N/A	$41.71 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest CMMB, OKYO, PLRX, and YARW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/13/2026	Q2 2026	YARW Yarrow Bioscience	-$0.18	-$3.51	-$3.33	-$3.51	$0.20 million	$0.10 million
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Latest CMMB, OKYO, PLRX, and YARW Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	YARW Yarrow Bioscience	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	6.41	6.41
OKYO OKYO Pharma	N/A	2.43	2.43
PLRX Pliant Therapeutics	N/A	9.90	9.90
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
OKYO OKYO Pharma	2.97%
PLRX Pliant Therapeutics	97.30%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
OKYO OKYO Pharma	40.46%
PLRX Pliant Therapeutics	8.74%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	12	7.25 million	6.38 million	Not Optionable
OKYO OKYO Pharma	5	52.48 million	31.25 million	Not Optionable
PLRX Pliant Therapeutics	49	61.92 million	56.51 million	Optionable
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

CMMB, OKYO, PLRX, and YARW Headlines

Recent News About These Companies

Yarrow Bioscience Inc YARW

September 15, 2026 | morningstar.comM

Yarrow Bioscience Closes $172.5 Million Public Offering

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Underwritten Equity Offering Agreement

September 14, 2026 | tipranks.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

September 14, 2026 | businesswire.com

Yarrow Bioscience Details Pricing for $150 Million Public Offering of Common Stock

September 14, 2026 | mobile.visionmonday.comM

Yarrow Bioscience Stock Falls 7% On Pricing Of $150 Mln Public Offering

September 13, 2026 | rttnews.com

Short Interest in Yarrow Bioscience (NASDAQ:YARW) Rises By 190.8%

September 13, 2026 | marketbeat.com

Yarrow Bioscience prices $150M public offering of common stock at $26 per share

September 11, 2026 | msn.com

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

September 10, 2026 | businesswire.com

Yarrow Bioscience Launches Public Offering of Common Stock

September 10, 2026 | finance.yahoo.com

Yarrow Bioscience Updates Strategy for Thyroid Autoimmune Pipeline

September 10, 2026 | tipranks.com

Yarrow Bioscience Announces Proposed Underwritten Public Offering

September 10, 2026 | businesswire.com

BlackRock Inc. Takes Position in Yarrow Bioscience $YARW

September 10, 2026 | marketbeat.com

40,697 Shares in Yarrow Bioscience $YARW Purchased by Two Sigma Securities LLC

September 7, 2026 | marketbeat.com

Yarrow Bioscience’s YB-101 Trial Targets Graves’ Disease, Raising New Investor Interest

September 4, 2026 | tipranks.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, OKYO, PLRX, and YARW Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$2.38 -0.10 (-4.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.12 (+4.87%)

As of 07:30 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

OKYO Pharma NASDAQ:OKYO

$1.35 +0.02 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.35 0.00 (0.00%)

As of 07:30 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Pliant Therapeutics NASDAQ:PLRX

$1.14 +0.03 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.14 +0.01 (+0.44%)

As of 07:40 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Yarrow Bioscience NASDAQ:YARW

$28.68 +0.38 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$28.66 -0.02 (-0.07%)

As of 07:30 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, OKYO, PLRX, and YARW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, OKYO, PLRX, and YARW Earnings

Compare Dividends

Latest CMMB, OKYO, PLRX, and YARW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, OKYO, PLRX, and YARW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, OKYO, PLRX, and YARW Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

OKYO Pharma NASDAQ:OKYO

Pliant Therapeutics NASDAQ:PLRX

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, OKYO, PLRX, and YARW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, OKYO, PLRX, and YARW Earnings

Compare Dividends

Latest CMMB, OKYO, PLRX, and YARW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, OKYO, PLRX, and YARW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, OKYO, PLRX, and YARW Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

OKYO Pharma NASDAQ:OKYO

Pliant Therapeutics NASDAQ:PLRX

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools